• Research, Science, and Trials

  Reata Pharmaceuticals – Omaveloxolone Update

  Posted by Christina Cordaro on February 10, 2021 at 7:44 am

  Reata Pharmaceuticals, Chairman & CEO Warren Huff shares this response letter of appreciation to the FA Community.

  This letter is in response to FARA’s February 5th communication and submission of the FA Community Petition: Food & Drug Administration & Reata Pharmaceuticals: Allow Individuals with Friedreich Ataxia Access to Omaveloxolone.

  To read the letter, click below:
  bit.ly/3aS3vTs

  Christina Cordaro replied 3 years, 7 months ago 1 Member · 0 Replies

  • FDA Approval
  • Reata Pharmaceuticals
  • scientific news
• 0 Replies

Log In to Reply